首页> 外国专利> Composition of lcrf, lcrf conjugate, peptide composition, lcrf complex conjugated to multiple ligand, polysorbate complex, conjugated lcrf complex, aqueous soluble stable, oral administration dosage form for the treatment of obesity, obesity treatment methods in a human or non-human mammalian patient, for prophylactic or interventional treatment of potential or developed obesity in a human or non-human mammalian patient and for prolongation of lcrf activity in an in vivo or in vitro system, and, composed

Composition of lcrf, lcrf conjugate, peptide composition, lcrf complex conjugated to multiple ligand, polysorbate complex, conjugated lcrf complex, aqueous soluble stable, oral administration dosage form for the treatment of obesity, obesity treatment methods in a human or non-human mammalian patient, for prophylactic or interventional treatment of potential or developed obesity in a human or non-human mammalian patient and for prolongation of lcrf activity in an in vivo or in vitro system, and, composed

机译：lcrf的组合物，lcrf缀合物，肽组合物，与多种配体缀合的lcrf复合物，聚山梨酸酯复合物，缀合的lcrf复合物，水溶性稳定剂，用于治疗肥胖的口服给药剂型，人类或非人类哺乳动物患者的肥胖治疗方法，用于在人类或非人类哺乳动物患者中预防或介入治疗潜在或已发展的肥胖症，以及延长体内或体外系统中lcrf的活性，

页面导航

摘要
著录项
相似文献

摘要

"LCRF COMPOSITION, LCRF CONJUGATE, PEPTIDE COMPOSITION, LCRF COMPLEX CONJUGATED TO MULTIPLE CONNECTION, POLYSTORBATE COMPLEX, CONJUGATED LCRF COMPLEX, WATERALLY SOLUBLE, STABLE, ORGANIZATION OF THE ADMINISTRATION OF ADMINISTRATION. OF OBESITY IN A HUMAN OR NON-HUMAN MAMMALIAN PATIENT, TREATMENT OF A PROPHYLATIC OR INTERVENTIONAL MODE OF POTENTIAL OR DEVELOPED OBESITY IN A HUMAN OR NON-HUMAN MAMMALIAN PATIENT AND EXTENSION OF LCRF ACTIVITY IN AN INITIATIVE SYSTEM ". Proteins and / or peptides, such as the luminal cholecystokinin releasing factor (LCRF), are conjugated to oligomers and amphiphilic polymers. Such conjugates can modulate the pharmacokinetic profile of proteins and / or peptides, thereby improving their clinical utility. Such conjugates can also stabilize and release proteins and / or peptides, such as LCRF, to receptors in the intestine without absorption into the bloodstream.

机译：“ LCRF组成，LCRF共轭，肽组成，LCRF复合物与多个连接相连接，聚苯乙烯酸盐复合物，LCLC复合物，水溶可溶，稳定，组织行政管理。肥胖症在人或兽患中的存在人类或非人类哺乳动物患者的潜在或发育性肥胖的预言性或干预性模式，以及初始系统中LCRF活性的扩展。蛋白质和/或肽，例如腔胆囊收缩素释放因子（LCRF），与低聚物和两亲性聚合物缀合。此类缀合物可以调节蛋白质和/或肽的药代动力学特征，从而改善其临床实用性。此类缀合物还可以稳定和释放蛋白质和/或肽（例如LCRF）至肠中的受体，而不吸收到血流中。

著录项

公开/公告号BR0016339A

专利类型
公开/公告日2002-08-27

原文格式PDF
申请/专利权人 NOBEX CORPORATION;
展开▼

申请/专利号BR20000016339
发明设计人 NNOCHIRI N. EKWURIBE;
展开▼

申请日2000-12-11
分类号A61K47/48;
国家 BR
入库时间 2022-08-22 00:46:10

相似文献

专利
外文文献